Almirall Eyes Top Specialty Dermatology Role After its AstraZeneca Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
Spain’s leading pharma company will use proceeds of its respiratory products sale to bulk up in dermatology, with the aim of becoming a global leader in the sector.
You may also be interested in...
AstraZeneca Rejigs Respiratory Franchise With Fresh Covis Deal
Having got hold of two COPD drugs from Spain's Almirall in 2014, AstraZeneca has passed Eklira and Duaklir onto old partner Covis Pharma as it focuses on more targeted respiratory therapies.
Almirall Knocked Back By US Woes, Could Affect Other Companies Too
Spain’s Almirall has suffered business setbacks in the US - including in its patient assistance program - that have forced the mid-sized drug maker to issue a profit warning, triggering of a sharp slide in its share price.
Almirall Knocked Back By US Woes, Could Affect Other Companies Too
Spain’s Almirall has suffered business setbacks in the US - including in its patient assistance program - that have forced the mid-sized drug maker to issue a profit warning, triggering of a sharp slide in its share price.